190 Pharmaceutical Companies Might Receive Subpoenas in Anti-Competitive Practices Investigation, FTC Says

The Federal Trade Commission on Wednesday announced that it plans to subpoena 190 drug companies in an investigation of possible anti-competitive practices in the pharmaceutical industry, the AP/Los Angeles Times reports. The subpoenas, which require approval from the Office of Management and Budget, would be part of a probe into whether pharmaceutical companies are suppressing competition by releasing authorized generic versions of their own brand-name drugs to coincide with the introduction of products from generic drug makers. For details, go to

http://www.kaisernetwork.org/daily_reports/rep_index.cfm?DR_ID=36314